Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
van Keep, Marjolijn, Gairy, Kerry, Seshagiri, Divyagiri, Thilakarathne, Pushpike, Lee, DawnVolume:
16
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-016-2633-2
Date:
December, 2016
File:
PDF, 1.03 MB
english, 2016